stockrow
Monday 9 November 2026
Export UPB’s income statement to Excel — free account
Upstream Bio, Inc.
UPBUpstream Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 million, up 20.4% from fiscal 2024.
- Revenue
- −17.5%
- EPS
- +1.35%
- Free cash flow
- +9.33%
Quarter to June 2026, against a year earlier
3.23
0.02
+0.62%
Follow UPB
Alert me
| Dec '25 | Dec '24 | Dec '23 | |
|---|---|---|---|
Piotroski F-Score |
2 | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 |
Altman Z-Score |
60.99 | 11.46 | — |
P/S ratio |
512.30 | 317.02 | 27.97 |
Altman Z″-Score (non-manufacturers) |
25.63 | 45.58 | 12.38 |
P/FCF ratio |
0.00 | 0.00 | 0.00 |
Beneish M-Score |
(2.81) | 6.55 | — |
P/Operating CF |
(47.73) | (38.31) | (4.76) |
P/B ratio |
4.30 | 1.60 | 0.00 |
Price to Tangible BV |
4.30 | 1.60 | 0.00 |
EV/Sales |
392.64 | 118.52 | (64.82) |
EV/EBITDA |
0.00 | 0.00 | 2.44 |
EV/Operating CF |
(8.41) | (4.75) | 2.77 |
EV/FCF |
(8.39) | (4.69) | 2.77 |
Quick Ratio |
25.44 | 43.87 | 16.87 |
Current Ratio |
26.15 | 44.63 | 17.96 |
Net Debt/EBITDA |
2.11 | 5.93 | 2.66 |
Debt/Assets |
0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 |
Asset Turnover |
0.01 | 0.01 | 0.00 |
Operating CF/Net income |
0.93 | 0.77 | 0.99 |
Capex/Depreciation |
0.13 | 0.33 | 0.12 |
| (35.43%) | (44.07%) | 0.00% | |
| (34.34%) | (25.51%) | 0.00% | |
ROIC |
0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(42.33%) | (16.29%) | (34.58%) |
Average Days of Receivables |
85.43 | 94.41 | 15.03 |
Research and Development Expense of Revenue |
4,793.48% | 2,656.79% | 1,336.09% |
Selling, General and Administrative Expense of Revenue |
925.33% | 724.39% | 449.37% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
362.02% | 253.33% | 143.99% |
Graham Net Nets |
0.23 | 0.62 | 3.23 |
Graham Number |
0.00 | 0.00 | 0.00 |
Earnings Yield |
(9.83%) | (113.24%) | (92.05%) |
Free Cash Flow Yield |
(9.14%) | (7.96%) | (83.71%) |
Revenue per Share |
0.05 | 0.17 | 0.81 |
Operating CF per Share |
(2.47) | (4.32) | (12.84) |
Capex per Share |
0.00 | (0.04) | (0.05) |
Free Cash Flow per Share |
(2.48) | (4.36) | (12.89) |
Cash per Share |
6.34 | 34.38 | 37.17 |
Shareholders Equity per Share |
6.31 | 34.34 | 36.50 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
6.31 | 34.34 | 36.50 |
Free Cash Flow |
(133.44) | (59.68) | (38.07) |
Working Capital |
338.35 | 468.42 | 110.48 |
Capital Expenditures |
(0.16) | (0.51) | (0.14) |
Net Current Asset Value |
337.80 | 467.29 | 107.61 |
EV/EBIT |
0.00 | 0.00 | 2.53 |
Capex to Sales |
0.06 | 0.22 | 0.06 |
Price to Operating Income |
0.00 | 0.00 | 0.00 |
| Other line items | |||
Depreciation/Fixed assets |
(2.35) | (2.69) | (7.55) |
Cash ROIC |
(19.59%) | (6.35%) | (17.49%) |
Accounts Receivable Turnover |
4.46 | 6.67 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 |
Average Receivables |
0.64 | 0.36 | — |
Average Payables |
3.38 | 3.02 | — |
Average Assets |
417.75 | 299.46 | — |
Average Common Equity |
404.81 | 173.36 | — |
Columns are period end dates · fundamentals updated 26 Oct 2026